March 5, 2020 / 12:23 PM / 24 days ago

BRIEF-Optinose Reports Q4 Loss Per Share Of $0.58

March 5 (Reuters) - OptiNose Inc:

* OPTINOSE REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

* Q4 REVENUE $11.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11.7 MILLION

* OPTINOSE - EXPECTS TOP-LINE RESULTS FROM BOTH CLINICAL TRIALS EVALUATING XHANCE AS A POTENTIAL TREATMENT FOR CHRONIC SINUSITIS IN SECOND HALF OF 2021

* EXPECTS FULL-YEAR 2020 XHANCE NET REVENUE TO MORE THAN DOUBLE

* Q4 LOSS PER SHARE $0.58

* EXPECTS XHANCE AVERAGE NET REVENUE PER PRESCRIPTION TO IMPROVE SUBSTANTIALLY FOR REMAINDER OF 2020.

* Q4 EARNINGS PER SHARE VIEW $-0.62, REVENUE VIEW $11.7 MILLION — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below